​

Amgen (AMGN) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Amgen Revenue Highlights

Latest Revenue (Y)

$28.19B

Latest Revenue (Q)

$8.50B

Main Segment (Y)

Other Products

Main Geography (Y)

UNITED STATES

Amgen Revenue by Period

Amgen Revenue by Year

DateRevenueChange
2023-12-31$28.19B7.09%
2022-12-31$26.32B1.32%
2021-12-31$25.98B2.18%
2020-12-31$25.42B8.83%
2019-12-31$23.36B-1.62%
2018-12-31$23.75B3.93%
2017-12-31$22.85B-0.62%
2016-12-31$22.99B6.14%
2015-12-31$21.66B7.97%
2014-12-31$20.06B7.43%
2013-12-31$18.68B8.17%
2012-12-31$17.27B10.80%
2011-12-31$15.58B3.51%
2010-12-31$15.05B2.81%
2009-12-31$14.64B-2.41%
2008-12-31$15.00B1.57%
2007-12-31$14.77B3.53%
2006-12-31$14.27B14.79%
2005-12-31$12.43B17.82%
2004-12-31$10.55B26.26%
2003-12-31$8.36B51.29%
2002-12-31$5.52B37.54%
2001-12-31$4.02B16.45%
2000-12-31$3.45B7.62%
1999-12-31$3.20B21.27%
1998-12-31$2.64B12.64%
1997-12-31$2.35B6.71%
1996-12-31$2.20B15.46%
1995-12-31$1.90B17.52%
1994-12-31$1.62B19.57%
1993-12-31$1.35B-

Amgen generated $28.19B in revenue during NA 2023, up 7.09% compared to the previous quarter, and up 118.71% compared to the same period a year ago.

Amgen Revenue by Quarter

DateRevenueChange
2024-09-30$8.50B2.04%
2024-06-30$8.33B12.67%
2024-03-31$7.40B-9.76%
2023-12-31$8.20B18.73%
2023-09-30$6.90B-1.19%
2023-06-30$6.99B14.43%
2023-03-31$6.11B-10.73%
2022-12-31$6.84B2.81%
2022-09-30$6.65B0.88%
2022-06-30$6.59B5.71%
2022-03-31$6.24B-8.88%
2021-12-31$6.85B2.09%
2021-09-30$6.71B2.76%
2021-06-30$6.53B10.59%
2021-03-31$5.90B-11.05%
2020-12-31$6.63B3.29%
2020-09-30$6.42B3.50%
2020-06-30$6.21B0.73%
2020-03-31$6.16B-0.58%
2019-12-31$6.20B8.02%
2019-09-30$5.74B-2.28%
2019-06-30$5.87B5.65%
2019-03-31$5.56B-10.80%
2018-12-31$6.23B5.52%
2018-09-30$5.90B-2.56%
2018-06-30$6.06B9.09%
2018-03-31$5.55B-4.27%
2017-12-31$5.80B0.50%
2017-09-30$5.77B-0.64%
2017-06-30$5.81B6.33%
2017-03-31$5.46B-8.40%
2016-12-31$5.96B2.65%
2016-09-30$5.81B2.16%
2016-06-30$5.69B2.91%
2016-03-31$5.53B-0.16%
2015-12-31$5.54B-3.27%
2015-09-30$5.72B6.57%
2015-06-30$5.37B6.70%
2015-03-31$5.03B-5.59%
2014-12-31$5.33B5.96%
2014-09-30$5.03B-2.88%
2014-06-30$5.18B14.58%
2014-03-31$4.52B-9.78%
2013-12-31$5.01B5.54%
2013-09-30$4.75B1.47%
2013-06-30$4.68B10.41%
2013-03-31$4.24B-4.14%
2012-12-31$4.42B2.36%
2012-09-30$4.32B-3.53%
2012-06-30$4.48B10.60%
2012-03-31$4.05B1.89%
2011-12-31$3.97B0.74%
2011-09-30$3.94B-0.38%
2011-06-30$3.96B6.83%
2011-03-31$3.71B-3.51%
2010-12-31$3.84B0.66%
2010-09-30$3.82B0.32%
2010-06-30$3.80B5.90%
2010-03-31$3.59B-5.70%
2009-12-31$3.81B-0.08%
2009-09-30$3.81B2.67%
2009-06-30$3.71B12.24%
2009-03-31$3.31B-11.81%
2008-12-31$3.75B-3.20%
2008-09-30$3.88B2.95%
2008-06-30$3.76B4.18%
2008-03-31$3.61B-

Amgen generated $8.50B in revenue during Q3 2024, up 2.04% compared to the previous quarter, and up 121.71% compared to the same period a year ago.

Amgen Revenue Breakdown

Amgen Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
XGEVA$2.11B$2.01B---
Aranesp$1.36B$1.42B---
BLINCYTO$861.00M----
ENBREL$3.70B$4.12B---
Evenity$1.16B$787.00M---
Kyprolis$1.40B$1.25B---
Nplate$1.48B$1.31B---
Otezla$2.19B$2.29B---
Other Products$5.26B$5.57B---
Product and Service, Other$1.28B$1.52B$1.68B$1.18B$1.16B
Prolia$4.05B$3.63B---
Vectibix$984.00M----
Repatha (evolocumab)$1.64B$1.30B---
Product-$17.30B$15.19B$13.78B$11.79B
Neulasta-$1.13B---

Amgen's latest annual revenue breakdown by segment (product or service), as of Dec 23: Other Products (19.16%), Prolia (14.74%), ENBREL (13.46%), Otezla (7.97%), XGEVA (7.69%), Repatha (evolocumab) (5.95%), Nplate (5.38%), Kyprolis (5.11%), Aranesp (4.96%), Product and Service, Other (4.66%), Evenity (4.22%), Vectibix (3.58%), and BLINCYTO (3.13%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
BLINCYTO$327.00M$244.00M------------------
ENBREL$825.00M$567.00M$1.01B$1.03B----------------
EVENITY$399.00M$342.00M$307.00M-----------------
KRYSTEXXA$310.00M$235.00M------------------
Kyprolis$378.00M$376.00M$350.00M$349.00M----------------
Nplate$456.00M$317.00M$386.00M$419.00M----------------
Otezla$564.00M$394.00M$629.00M$567.00M----------------
Prolia$1.04B$999.00M$1.11B$986.00M----------------
Repatha (evolocumab)$567.00M$517.00M$417.00M$406.00M----------------
TEPEZZA$488.00M$424.00M------------------
TEZSPIRE$269.00M$173.00M------------------
Vectibix$282.00M$247.00M------------------
XGEVA$541.00M$561.00M$527.00M$519.00M----------------
Aranesp$337.00M$349.00M$319.00M$323.00M----------------
Product and Service, Other-$329.00M$363.00M$355.00M$303.00M$259.00M$287.00M$415.00M$313.00M$507.00M$575.00M$386.00M$412.00M$309.00M$319.00M$298.00M$267.00M$316.00M$274.00M$297.00M
Other Products-$1.37B$200.00M$1.64B----------------
Product---$6.55B$6.55B$6.27B--------------

Amgen's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Prolia (15.39%), ENBREL (12.15%), Repatha (evolocumab) (8.35%), Otezla (8.31%), XGEVA (7.97%), TEPEZZA (7.19%), Nplate (6.72%), EVENITY (5.88%), Kyprolis (5.57%), Aranesp (4.96%), BLINCYTO (4.82%), KRYSTEXXA (4.57%), Vectibix (4.15%), and TEZSPIRE (3.96%).

Amgen Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
UNITED STATES$19.81B$18.59B$1.43B$1.41B$1.46B
Non-US$8.38B$7.73B$584.00M$494.00M$478.00M

Amgen's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (70.26%), and Non-US (29.74%).

Quarterly Revenue by Country

CountrySep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Non-US$2.17B$2.15B$2.71B$1.86B$143.00M$152.00M$126.00M$132.00M$142.00M$134.00M$145.00M$133.00M$134.00M$133.00M$118.00M$117.00M$126.00M$123.00M$120.00M$120.00M
UNITED STATES$5.98B$4.97B$6.40B$4.69B$387.00M$384.00M$358.00M$363.00M$391.00M$368.00M$372.00M$355.00M$334.00M$369.00M$363.00M$318.00M$355.00M$366.00M$356.00M$379.00M

Amgen's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (73.35%), and Non-US (26.65%).

Amgen Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
JNJJohnson & Johnson$85.15B$22.47B
MRKMerck$60.12B$16.66B
PFEPfizer$58.50B$17.70B
ABBVAbbVie$54.32B$14.46B
BMYBristol-Myers Squibb Company$45.01B$11.89B
LLYEli Lilly and Company$34.12B$11.44B
AMGNAmgen$28.19B$8.50B
GILDGilead Sciences$27.12B$7.55B
BIIBBiogen$9.84B$2.47B

AMGN Revenue FAQ

What is Amgen’s yearly revenue?

Amgen's yearly revenue for 2023 was $28.19B, representing an increase of 7.09% compared to 2022. The company's yearly revenue for 2022 was $26.32B, representing an increase of 1.32% compared to 2021. AMGN's yearly revenue for 2021 was $25.98B, representing an increase of 2.18% compared to 2020.

What is Amgen’s quarterly revenue?

Amgen's quarterly revenue for Q3 2024 was $8.5B, a 2.04% increase from the previous quarter (Q2 2024), and a 23.18% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $8.33B, a 12.67% increase from the previous quarter (Q1 2024), and a 19.28% increase year-over-year (Q2 2023). AMGN's quarterly revenue for Q1 2024 was $7.4B, a -9.76% decrease from the previous quarter (Q4 2023), and a 21.15% increase year-over-year (Q1 2023).

What is Amgen’s revenue growth rate?

Amgen's revenue growth rate for the last 3 years (2021-2023) was 8.51%, and for the last 5 years (2019-2023) was 20.67%.

What are Amgen’s revenue streams?

Amgen's revenue streams in c 23 are XGEVA, Aranesp, BLINCYTO, ENBREL, Evenity, Kyprolis, Nplate, Otezla, Other Products, Product and Service, Other, Prolia, Vectibix, and Repatha (evolocumab). XGEVA generated $2.11B in revenue, accounting 7.69% of the company's total revenue, up 4.87% year-over-year. Aranesp generated $1.36B in revenue, accounting 4.96% of the company's total revenue, down -4.15% year-over-year. BLINCYTO generated $861M in revenue, accounting 3.13% of the company's total revenue ENBREL generated $3.7B in revenue, accounting 13.46% of the company's total revenue, down -10.20% year-over-year. Evenity generated $1.16B in revenue, accounting 4.22% of the company's total revenue, up 47.40% year-over-year. Kyprolis generated $1.4B in revenue, accounting 5.11% of the company's total revenue, up 12.51% year-over-year. Nplate generated $1.48B in revenue, accounting 5.38% of the company's total revenue, up 13.01% year-over-year. Otezla generated $2.19B in revenue, accounting 7.97% of the company's total revenue, down -4.37% year-over-year. Other Products generated $5.26B in revenue, accounting 19.16% of the company's total revenue, down -5.51% year-over-year. Product and Service, Other generated $1.28B in revenue, accounting 4.66% of the company's total revenue, down -15.90% year-over-year. Prolia generated $4.05B in revenue, accounting 14.74% of the company's total revenue, up 11.58% year-over-year. Vectibix generated $984M in revenue, accounting 3.58% of the company's total revenue Repatha (evolocumab) generated $1.64B in revenue, accounting 5.95% of the company's total revenue, up 26.16% year-over-year.

What is Amgen’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Amgen was Other Products. This segment made a revenue of $5.26B, representing 19.16% of the company's total revenue.